<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8629">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994615</url>
  </required_header>
  <id_info>
    <org_study_id>108627</org_study_id>
    <nct_id>NCT02994615</nct_id>
  </id_info>
  <brief_title>Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy</brief_title>
  <acronym>PRIMARy</acronym>
  <official_title>Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy: The Index of MicrovAscular Resistance (IMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be
      assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter
      monitor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IMR in patients with hypertrophic cardiomyopathy (HCM) versus controls</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular tachycardia</measure>
    <time_frame>6 months</time_frame>
    <description>Measured during 48 h recording after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest pain - Canadian Cardiovascular Society (CCS) class</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shortness of breath - NYHA class</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>hypertrophic cardiomyopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic hypertrophic cardiomyopathy versus controls (patients undergoing
        coronary angiography and FFR
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80

          -  Already have an indication for coronary angiography

          -  Previous diagnosis of hypertrophic cardiomyopathy (unless control)

        Exclusion Criteria:

          -  Fractional flow reserve found to be significant (FFR &lt; 0.8)

          -  Already have a condition associated with or likely to be associated with an elevated
             IMR (diabetes, cardiac syndrome X, takotsubo cardiomyopathy, hypertensive
             cardiomyopathy, severe aortic stenosis, STEMI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassandra Wagner, BSc</last_name>
    <phone>5196858500</phone>
    <phone_ext>35626</phone_ext>
    <email>cassandra.wagner@lhsc.on.ca</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 15, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Shahar Lavi</investigator_full_name>
    <investigator_title>Director of Cardiovascular Interventional Research</investigator_title>
  </responsible_party>
  <keyword>Index of Microvascular Resistance</keyword>
  <keyword>Microvascular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
